Clinical, Molecular, and Genetic Bases of Rare Inherited Coagulation Disorders (RICDs)

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: closed (30 September 2020) | Viewed by 2908

Special Issue Editors


E-Mail Website
Guest Editor
Department of Biomedical Sciences, Humanitas University, Via Manzoni 113, 20089 Rozzano, Milan, Italy
Interests: genetic and molecular bases of rare inherited coagulopathies (fibrinogen, factor V, and factor XI deficiencies); genetic bases of complex traits (multiple sclerosis, Parkinson’s disease, myocardial infarction); association studies (candidate genes, genome-wide association studies); metabolism of RNA (alternative splicing, microRNA-mediated regulation)
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Co-Guest Editor
Department of Biomedical Sciences, Humanitas University, Via Manzoni 113, 20089 Rozzano, Milan, Italy
Interests: genetic and molecular bases of rare inherited coagulopathies; genetic bases of complex diseases; association studies (common and rare variants analysis); metabolism of RNA; bioinformatics

Special Issue Information

Dear Colleagues,

Rare Inherited Coagulation Disorders (RICDs), which are also frequently referred to as Rare Bleeding Disorders (RBDs), mainly comprise bleeding disorders with a very low prevalence in the general population. RICDs include inherited deficiencies or defects in fibrinogen (FI), prothrombin (FII), and coagulation factors V (FV), VII (FVII), X (FX), XI (FXI), and XIII (FXIII). These diseases can present as the isolated deficiency of one factor or, more rarely, as the combined deficiency of two (combined FV/FVIII deficiency) or many (vitamin K-dependent coagulation factor deficiency) coagulation factors. Collectively, RICDs account for approximately 3–5% of the coagulation disorders, the remaining 95–97% being represented by the more common X-linked hemophilias (deficiency of factor VIII or factor IX) and von Willebrand factor.

Notwithstanding the many efforts to better assess the epidemiology and underlying molecular mechanisms of RICDs, data on “true” prevalence rates and mutational spectra are still not comprehensive, especially for developing countries. In addition, even if a relatively large number of patients have been screened for mutations in the candidate genes, in most of the cases the underlying molecular mechanism has not been experimentally validated. This, besides leaving a knowledge gap between genetic data and the related pathophysiologic processes, is also responsible for a non-negligible proportion of errors in reporting “true” causal variants, a problem that is particularly frequent in rare recessive diseases.

In this respect, this Special Issue of Biomedicines will focus on providing updated mutational spectra, novel insights into genotype–phenotype correlations, as well as on giving insights into the molecular pathogenesis of RICDs. Indeed, spontaneous mutants in the population can represent a useful tool to inspect critical residues for coagulation factor assembly, secretion, function, and interaction with other proteins, as well as to elucidate molecular mechanisms underlying mRNA processing. This approach, that in the past century has been fundamental to the discovery of most of the coagulation factors and to understanding the mechanisms of blood coagulation, still represents an extraordinary tool for studying the molecular details of structure–function relationships of coagulation factors and for highlighting novel strategies to improve RICDs therapy, which in most cases is based on the availability of a suitable factor-replacement product.

Prof. Dr. Rosanna Asselta
Dr. Elvezia Maria Paraboschi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • rare coagulation factor deficiencies;
  • genetic bases;
  • mutations;
  • pathogenic mechanisms;
  • expression of recombinant proteins;
  • RNA processing;
  • population genetics;
  • clinical spectrum.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 3013 KiB  
Article
A Novel Nonsense Mutation in FGB (c.1421G>A; p.Trp474Ter) in the Beta Chain of Fibrinogen Causing Hypofibrinogenemia with Bleeding Phenotype
by Tomas Simurda, Rui Vilar, Jana Zolkova, Eliska Ceznerova, Zuzana Kolkova, Dusan Loderer, Marguerite Neerman-Arbez, Alessandro Casini, Monika Brunclikova, Ingrid Skornova, Miroslava Dobrotova, Marian Grendar, Jan Stasko and Peter Kubisz
Biomedicines 2020, 8(12), 605; https://doi.org/10.3390/biomedicines8120605 - 13 Dec 2020
Cited by 28 | Viewed by 2540
Abstract
Congenital hypofibrinogenemia is a rare bleeding disorder characterized by a proportional decrease of functional and antigenic fibrinogen levels. Hypofibrinogenemia can be considered the phenotypic expression of heterozygous loss of function mutations occurring within one of the three fibrinogen genes (FGA, FGB [...] Read more.
Congenital hypofibrinogenemia is a rare bleeding disorder characterized by a proportional decrease of functional and antigenic fibrinogen levels. Hypofibrinogenemia can be considered the phenotypic expression of heterozygous loss of function mutations occurring within one of the three fibrinogen genes (FGA, FGB, and FGG). Clinical manifestations are highly variable; most patients are usually asymptomatic, but may appear with mild to severe bleeding or thrombotic complications. We have sequenced all exons of the FGA, FGB, and FGG genes using the DNA isolated from the peripheral blood in two unrelated probands with mild hypofibrinogenemia. Coagulation screening, global hemostasis, and functional analysis tests were performed. Molecular modeling was used to predict the defect of synthesis and structural changes of the identified mutation. DNA sequencing revealed a novel heterozygous variant c.1421G>A in exon 8 of the FGB gene encoding a Bβ chain (p.Trp474Ter) in both patients. Clinical data from patients showed bleeding episodes. Protein modelling confirmed changes in the secondary structure of the molecule, with the loss of three β sheet arrangements. As expected by the low fibrinogen levels, turbidity analyses showed a reduced fibrin polymerisation and imaging difference in thickness fibrin fibers. We have to emphasize that our patients have a quantitative fibrinogen disorder; therefore, the reduced function is due to the reduced concentration of fibrinogen, since the Bβ chains carrying the mutation predicted to be retained inside the cell. The study of fibrinogen molecules using protein modelling may help us to understand causality and effect of novel genetic mutations. Full article
Show Figures

Figure 1

Back to TopTop